Tango Therapeutics Inc Stock, NASDAQ:TNGX
100 Binney Street, Unit 700, Cambridge, Massachusetts 02142
United States of America
Number of Employees: 91
Tango Therapeutics, Inc. operates as a biotechnology company, which engages in discovering and delivering precision cancer medicines. Its primary program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.